Design, synthesis, and evaluation of aminopyrazolopyrimidopyridone derivatives as RETV804M and RETG810C inhibitors based on a “chemical adaptation” strategy
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.110385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Jieman Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou 341000, China. Hauptthemen laut MEDLINE: Drug Design, Proto-Oncogene Proteins c-ret, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Gannan Normal University, National Natural Science Foundation of China, Jiangxi Provincial Natural Science Foundation.
Abstract (Originalsprache)
Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is a well-recognized drug target for cancer treatment. Despite the FDA approval of two selective second-generation RET inhibitors, selpercatinib and pralsetinib, acquired resistance through solvent-front mutations has been identified rapidly. RETG810 mutations at the solvent front site have been identified as the major on-target mutations contributing to resistance against selpercatinib and pralsetinib. Therefore, the development of next-generation RET inhibitors to overcome acquired solvent-front resistance mutations is urgently needed. In this study, a class of aminopyrazolpyrimidopyridone derivatives, such as RETV804M gatekeeper mutations and RETG810C solvent-front mutant inhibitors, were designed and synthesized to overcome resistance to second-generation RET inhibitors. One of the optimal compounds, 11ic, inhibited the proliferation of BaF3 cells harboring the CCDC6-RETV804M and CCDC6-RETG810C mutations, with IC50 values of 0.0208 μM and 0.096 μM, respectively. It presented a favorable oral pharmacokinetic profile, with an oral bioavailability of 26.9%, which exceeded that of our previously reported compound. Compound 11ic might be a promising lead compound for the development of novel RETV804M and RETG810C inhibitors to overcome clinical acquired resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou 341000, China.
- Jiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou 341000, China. Electronic address: shenjiayi890813@163.com.
Förderung
- Gannan Normal University
- National Natural Science Foundation of China
- Jiangxi Provincial Natural Science Foundation
Zitieren
APA
Lin, J., Jia, S., Wu, J., Li, A., Zhu, J., Li, Y., Liu, M., & Shen, J. (2026). Design, synthesis, and evaluation of aminopyrazolopyrimidopyridone derivatives as RETV804M and RETG810C inhibitors based on a “chemical adaptation” strategy. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110385
Vancouver
Lin J, Jia S, Wu J, Li A, Zhu J, Li Y, et al. Design, synthesis, and evaluation of aminopyrazolopyrimidopyridone derivatives as RETV804M and RETG810C inhibitors based on a “chemical adaptation” strategy. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110385
BibTeX
@article{Lin2026,
author = {Lin, Jieman and Jia, Shuyu and Wu, Jianjun and Li, Anzhi and Zhu, Jiaqing and Li, Yongdong and Liu, Meipin and Shen, Jiayi},
title = {Design, synthesis, and evaluation of aminopyrazolopyrimidopyridone derivatives as RETV804M and RETG810C inhibitors based on a “chemical adaptation” strategy},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.110385}
}
EUVIMED